Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Oncimmune distributor gets approval for 'EarlyCDT-Lung' in Israel

Wed 15 May 2019 15:27 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced on Wednesday that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of the 'EarlyCDT-Lung' product in Israel.

The AIM-traded firm said that an age standardised basis, Israel's lung cancer mortality rate was 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region.

Lung cancer was responsible for more cancer-related deaths than any other cancer in the country.

"We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel," said chief executive officer Dr Adam Hill.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More AIM news from ShareCast

    No results were found